CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York

From TechCrunch

By Julie Bort

August 18, 2026

Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York

Daniel Ek’s body-scanning startup Neko Health opens first US office, in New York

Neko Health’s promised U.S. expansion arrives on September 24, when the health-scanning startup opens its first American office. It will be located in SoHo, Manhattan’s home of luxury shopping, at 300 Lafayette Street.

Neko was founded by Spotify co-founder and CEO Daniel Ek and Hjalmar Nilsonne, who serves as Neko’s CEO. The company says that more than 25,000 New Yorkers have joined a waitlist.

As we previously reported, Neko Health has developed proprietary body-scanning technology, which it pairs with bloodwork and data from fitness devices to assess a person’s health. Currently, the startup has locations in the U.K. and Sweden. When it raised a $700 million Series C last month, it said that 100,000 people already had scans.

Neko is among a growing number of health-scanning companies created by tech founders or backed by VCs. For instance, Midjourney, the AI lab best known for its AI image and video creation model and website, is also creating a body scanner, which it plans to integrate into a spa experience. It plans to open in San Francisco in 2027. Tony Robbins and Peter Diamandis also have a longevity company called Fountain Life that does scans and health assessments. Function Health, co-founded by well-known wellness podcaster Dr. Mark Hyman, offers blood testing, and it added body scans after acquiring the startup Ezra. Function just took on a $450 million loan from General Catalyst’s Customer Value Fund, where companies repay the money via profit-sharing arrangements.

View original article on techcrunch.com

Most Recent

Circuit Breaker Labs hopes to make AI safer for your kids (and you)

With all the talk about how AI might one day kill us all, it's easy to forget that AI has already harmed some people psychologically. Circuit Breaker Labs has created "crash-test dummies" to solve that.

Oct 2, 2026

Kevin Mandia’s new ‘agent swarm’ security startup Armadin raises $255.5M at $2.5B valuation

Kevin Mandia, best known as the founder of Mandiant, has a new startup that is using agent swarms to test and protect enterprises.

Oct 1, 2026

Valor, Atreides, and Sequoia back AI startup Flow Engineering at $750M valuation

Flow Engineering, which is bringing AI agents to hardware design, also landed Roelof Botha as an angel investor and board member.

Sep 30, 2026

Is Neko Health’s body scan worth it? Spotify billionaire’s startup has come to America

Watch as Neko Health Investor Farooq Abbasi joins Equity to explain the bet on preventative healthcare, competition and what comes next.

Sep 30, 2026

Similar Posts

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

Terry Myerson retires as Truveta CEO, with co-founders stepping in to lead $1B health data startup

Truveta co-founders Jay Nanduri and Ryan Ahern will serve as interim co-CEOs of the health data company, which Myerson helped build from a pandemic-era idea into a business with 500 employees and 30 member health systems.

Sep 15, 2026

Function Health buys Ezra, launches full-body scan for a third of the price

Function Health acquired full-body MRI company Ezra to add advanced imaging to its preventive health membership platform.

May 4, 2025

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Nue Life Health is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health tracking app. Previously, the app was only offered as part of its own internal service. However, the startup is now opening up its “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy, not just […]

Jun 15, 2023